Quince Therapeutics Enters Strategic Relationship With Option Care Health To Support The Commercial Development And Efficient Launch Of Quince's Lead Asset, Encapsulated Dexamethasone Sodium Phosphate In The U.S
Author: Benzinga Newsdesk | August 07, 2025 07:09am
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has formed a strategic relationship with Option Care Health, Inc. (NASDAQ:OPCH), the nation's largest independent provider of home and ambulatory infusion services, to support the commercial development and efficient launch of Quince's lead asset, encapsulated dexamethasone sodium phosphate (eDSP) in the U.S., assuming
The strategic relationship will leverage Option Care Health's robust network of specialty pharmacies and ambulatory infusion suites to provide for the administration of eDSP in an effective and efficient way while delivering this innovative treatment to patients. With a national footprint of more than 90 full-service pharmacies and 180-plus ambulatory infusion suites located across the U.S., Option Care Health is well positioned to dramatically enhance Quince's ability to provide patients with Ataxia-Telangiectasia (A-T) access to eDSP treatment, including greater geographic flexibility to match patient locations and eDSP administration needs, an improved and standardized patient journey with higher control and consistency across eDSP administration sites, the benefit of contracting with a single provider versus multiple individual academic centers of excellence, and scalability to treat patients in additional targeted indications such as Duchenne muscular dystrophy (DMD). Additionally, the engagement will be supported by Option Care Health's comprehensive suite of enhanced service capabilities, including third-party logistics (3PL) and inventory distribution management, program management, customized patient registration and hub support, clinician-delivered services, physician reporting, and data collection and reporting. positive study results and subsequent regulatory approval.
Posted In: OPCH QNCX
